Recursion Pharmaceuticals Stock Price Down -1.18% on Friday, 03/24/23: Read This Before You Buy!
March 29, 2023
Trending News 🌥️
Recursion Pharmaceuticals ($NASDAQ:RXRX) Inc. (REC) stock has been on a rollercoaster ride for the last few weeks, with Friday, 03/24/23 being no exception. On that day, the company’s share price decreased by 1.18% from its closing value on Thursday, ending the day at $XX.XX. As an investor, it is important to stay informed of the latest news and trends in the stock market before making an investment decision. Recursion Pharmaceuticals Inc. is a biotechnology company that focuses on developing treatments for rare and complex diseases, using Artificial Intelligence and genomic technologies. The company has recently made several innovations that have caught the attention of investors and analysts alike. Despite this, the stock price has been volatile over the past few weeks, with Friday’s dip being the latest example.
Before investing in Recursion Pharmaceuticals Inc. stock, it is important to do your research and understand the risks involved in investing in such a volatile stock. Analysts have mixed opinions on whether this dip is a good buying opportunity or not, so it is essential to make sure you are making an informed decision. It is also important to remember that stock prices can experience sudden drops or rises without any warning and that it is best to consult a financial advisor before making any investments.
Price History
On Friday, 03/24/23, RECURSION PHARMACEUTICALS Inc. saw its stock price fall by -1.18%, despite having opened with a 0.4% increase from the previous closing price. RECURSION PHARMACEUTICALS Inc. opened on Monday, 03/24/23, at $6.7 and closed at $6.7, making the overall performance of the day a -1.18% decrease from opening price. This news can be concerning for investors, as the stock performance of RECURSION PHARMACEUTICALS Inc. was not as expected. As such, anyone interested in investing in the company should thoroughly research and analyze the current market performance of RECURSION PHARMACEUTICALS Inc. before making a purchase decision. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Recursion Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 39.68 | -239.48 | -603.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Recursion Pharmaceuticals. More…
| Operations | Investing | Financing |
| -83.52 | 193.25 | 154.34 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Recursion Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 701.29 | 215.48 | 2.23 |
Key Ratios Snapshot
Some of the financial key ratios for Recursion Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 185.2% | – | -603.4% |
| FCF Margin | ROE | ROA |
| -304.6% | -34.2% | -21.3% |
Analysis
At GoodWhale, we offer a comprehensive evaluation of RECURSION PHARMACEUTICALS to help investors get an accurate understanding of the company’s finances. Our Risk Rating system classifies RECURSION PHARMACEUTICALS as a medium risk investment in terms of financial and business aspects. To gain a more detailed insight into the company’s financial state of affairs, investors can become a registered user of GoodWhale and check out our risk warnings in the balance sheet, cashflow statement and financial journal. These warnings can be useful in helping investors make informed decisions when investing in RECURSION PHARMACEUTICALS. More…
Peers
The company was founded in 2013 by Christopher R. Gibson and Brendan Frey. Vor Biopharma Inc, EQRx Inc, and Lantern Pharma Inc are all competitors of Recursion Pharmaceuticals Inc.
– Vor Biopharma Inc ($NASDAQ:VOR)
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with serious and life-threatening diseases. The company’s lead product candidate is VOR51, a first-in-class immunotherapy for the treatment of solid tumors. Vor Biopharma is also developing VOR33, a novel immunotherapy for the treatment of hematologic malignancies, and VOR19, a novel immunotherapy for the treatment of autoimmune diseases.
– EQRx Inc ($NASDAQ:EQRX)
EQRx is a biopharmaceutical company that focuses on the development of innovative therapies for patients with serious diseases. The company has a market cap of $2.42 billion and a return on equity of -12.39%. EQRx is headquartered in Cambridge, Massachusetts.
– Lantern Pharma Inc ($NASDAQ:LTRN)
Lantern Pharma Inc has a market cap of 46.57M as of 2022. The company’s return on equity is 16.74%.
Lantern Pharma Inc is a clinical stage biopharmaceutical company specializing in the development of precision medicines for the treatment of cancer. The company’s lead product candidate, LP-100, is a novel targeted therapy in development for the treatment of non-small cell lung cancer.
Summary
Recursion Pharmaceuticals Inc. (RCUR) stock price decreased by 1.18% on Friday, 03/24/23. Investors should review the company’s financials and competitive landscape before making an investment decision. Analysts suggest that it is important to consider the company’s cash position, total debt and recent developments.
Additionally, investors should research the company’s management team, products, competitive advantages and business model to gain a better understanding of the company’s potential for growth. Finally, investors should look for any red flags such as high debt levels, decreasing revenue, or low market share. Overall, it is important to be aware of the risks when investing in Recursion Pharmaceuticals Inc. and make sure to research the stock before investing.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
